IKZF1 Deletion

CI-VAR-00000629Explore in graph →CIViC 200

Curated evidence

Evidence by cancer (17 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–17 of 17 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia2
IKZF1 Deletion	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID625 IKZF1 deletions in patients with BCR-ABL–positive adult acute lymphoblastic leukemia were associated with reduced disease-free survival compared to wild type patients. PMID 19770381 · Martinelli et al., 2009 · Open in CIViC	civic
IKZF1 Deletion	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID626 A targeted copy number screen of 131 precursor B-ALL cases revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates. Furthermore non-high-risk patie… (full text at CIViC) PMID 20445578 · Kuiper et al., 2010 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Childhood B-cell Acute Lymphoblastic Leukemia4unmapped disease
IKZF1 Deletion	(prognostic)	Prognostic	B	Supports Poor Outcome	4	rejected	EID7391 IKZF1 deletions and mutations are associated with adverse outcome (including increased risk of relapse and other adverse events and increased probability of MRD at the end of induction) in patients wi… (full text at CIViC) PMID 19129520 · Mullighan et al., 2009 · Open in CIViC	civic
IKZF1 Deletion	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID7542 Pediatric B-ALL patients with IKZF1 deletions treated between 1998 and 2008 on the European Organisation for Research and Treatment of Cancer (EORTC-CLG) trial 58951 had a lower event-free survival … (full text at CIViC) PMID 26050650 · Clappier et al., 2015 · Open in CIViC	civic
IKZF1 Deletion	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID7543 Pediatric B-ALL patients with IKZF1 deletions treated on Berlin-Frankfurt-Münster Study Group trial ALL-BFM 2000 had a lower 5-year event-free survival (0.69±0.05 vs. 0.85±0.01; P<0.0001) compared to … (full text at CIViC) PMID 22875627 · Dörge et al., 2013 · Open in CIViC	civic
IKZF1 Deletion	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID7544 Among pediatric B-lymphoblastic Leukemia (B-ALL) patients treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 05-001, IKZF1 deletion was present in 62 of 385 (16%) assessed patients… (full text at CIViC) PMID 29941458 · Vrooman et al., 2018 · Open in CIViC	civic